CERBA-RESEARCH
24.8.2021 14:03:02 CEST | Business Wire | Press release
Cerba Research , a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:
- Cutting-edge flow cytometry technologies
- Exploratory as well as In Vitro Diagnostic histopathology services
- Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues
Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.
Mario Papillon, CEO of Cerba Research comments: “This milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company.”
“We are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,” says Hua Chien Chen, CEO, ACT Genomics.
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
About ACT Genomics
ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore, Tokyo, and Wales (U.K.). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005259/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release
The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink
Kinaxis Advances Large-Scale Supply Chain Optimization with NVIDIA AI16.3.2026 21:30:00 CET | Press release
Achieves up to 12X faster end-to-end planning performance in large-scale enterprise models Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced a new milestone in advancing large-scale supply chain optimization within the Kinaxis Maestro™ platform. Maestro already delivers high-performance optimization across complex global supply chains, and Kinaxis is now extending that leadership by leveraging GPU acceleration powered by NVIDIA cuOpt™ and NVIDIA AI infrastructure. As supply chains grow in scale and complexity, planning models must reconcile tens of millions of variables across extended time horizons and multiple planning levels. As model size expands, the number of potential decisions can scale into billions, dramatically increasing computational needs. Organizations are no longer constrained by insight alone. They are constrained by how quickly they can iterate. In testing on a large-scale semiconductor planning model with nearly 50 million decis
Lattice Joins NVIDIA Halos Ecosystem to Advance Safety for Physical AI with Holoscan Sensor Bridge16.3.2026 21:30:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced it has joined the NVIDIA Halos AI Systems Inspection Lab ecosystem, the first ANSI National Accreditation Board (ANAB) accredited inspection lab for AI-driven physical systems. Announced at the NVIDIA GTC 2026, Lattice will engage with NVIDIA and other Halos ecosystem members to build Halos-certified Holoscan Sensor Bridge-based designs for physical AI and to help shape best practices as the industry evolves. “Physical AI is rapidly moving from controlled environments into the real world, where safety, reliability, and trust are paramount,” said Raemin Wang, Vice President, Segment Marketing, Lattice Semiconductor. “Through this collaboration, Lattice looks forward to contributing our expertise in low power FPGAs and award-winning solution stacks to enable scalable, trusted physical AI systems across robotics, industrial automation, and autonomous applications.” NVIDIA Halos is a comprehensive full
Lenovo Brings Production-Scale AI to Global Sports: Enhancing Fan Experience, Driving Revenue Growth, Boosting Performance, and Improving Operational Efficiency with NVIDIA16.3.2026 21:30:00 CET | Press release
Multiyear collaboration introduces new solutions spanning Sports Intelligence, Operations, and Media & Content. At NVIDIA GTC today, Lenovo (HKSE: 992) (ADR: LNVGY) announced an expanded multiyear collaboration with NVIDIA to help the global sports industry deploy production-scale AI across mission-critical environments, transforming live data into revenue growth, operational resilience, and real-time decision advantage. The global sports technology market is projected to grow from $23 billion in 2025 to more than $60 billion by 2030. Global sports events represent some of the most complex and demanding operating environments in any industry, combining unprecedented scale, technical sophistication, and public visibility. These events engage billions of viewers worldwide, generate and process petabytes of data in real time, and require highly coordinated, distributed operations across multiple countries, all within a context where reliability, resilience, and uninterrupted performance a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom